Siva Naga S Yarrarapu, Amandeep Goyal, Vikramaditya Samala Venkata, Viraj Panchal, Barath Prashanth Sivasubramanian, Doantrang T Du, Roopesh Sai Jakulla, Hema Pamulapati, Mazhar A Afaq, Steven Owens, Tarun Dalia
Statin-intolerance (SI) has prevalence between 8.0 % and 10 %, and muscular complaints are the most common reason for discontinuation. Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood. Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17-28 % in SI. The CLEAR OUTCOME trial established significant cardiovascular benefits with BA...
March 21, 2024: Journal of Cardiology